rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agenți antineoplazici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
rozlytrek 100 mg
roche farma ag - germania - entrectinibum - caps. - 100mg - inhibitori de protein-kinaza
rozlytrek 200 mg
roche farma ag - germania - entrectinibum - caps. - 200mg - inhibitori de protein-kinaza
erlotinib teva 25 mg
pliva croatia ltd. - croatia - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib teva 100 mg
pliva croatia ltd. - croatia - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib teva 150 mg
pliva croatia ltd. - croatia - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib ratiopharm 100 mg
pliva hrvatska d.o.o. (pliva croatia ltd.) - polonia - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib ratiopharm 150 mg
pliva hrvatska d.o.o. (pliva croatia ltd.) - polonia - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib ratiopharm 25 mg
pliva hrvatska d.o.o. (pliva croatia ltd.) - polonia - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza
erlotinib glenmark 100 mg
remedica ltd. - cipru - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza